# OnCo record nct06445062 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06445062/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06445062", "NCT06445062" ;
  schema:name "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Daraxonrasib, Bevacizumab, Cetuximab in colorectal cancer and pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06445062/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06445062> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2024-05-24" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/zoldonrasib/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> .